07:26 AM EDT, 08/13/2025 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) reported Wednesday a Q2 net loss of $0.46 per diluted share, wider than a loss of $0.13 a year earlier.

Two analysts polled by FactSet expected a loss of $0.39.

Total revenue for the quarter ended June 30 was $15.7 million, compared with $500,000 a year earlier.

Analysts surveyed by FactSet expected $13.8 million.

As of June 30, the company said it had $240.1 million in cash, cash equivalents, and short-term investments, and expected it could fund operations through at least the next three years.

The company's shares were over 6% higher in recent premarket activity Wednesday.